Connect with us

Spread & Containment

J.P. Morgan Says These 2 Stocks Will Surge Over 25% From Current Levels

J.P. Morgan Says These 2 Stocks Will Surge Over 25% From Current Levels



Stock markets saw spectacular drop yesterday, as rising hospitalizations in states such as Texas and Arizona promoted fears that an uptick in coronavirus cases could cause more economic damage. It’s a clear sign that traders are not going to be easily reassured in the current crisis. 

Yet, according to J.P. Morgan strategist Nikolaos Panigirtzoglou there's a light at the end of the tunnel. Panigirtzoglou argues that the massive amount of cash currently in the financial system could be the spark that pushes risk assets higher, noting that billions could be pumped into equities. This potential, however, could come at the expense of bonds as portfolios are rebalanced.

To support this stance, the strategist cited the fact that $1.2 trillion have been put into money-market funds, with fund managers holding on to cash, $591 billion overall, like never before, based on data reported by Bank of America. This means that investors can still prop up the market even during a tumultuous period of time.  

“Investors are still underweight equities and signs of overextension are confined to momentum traders. There is still plenty of room for investors to raise their equity allocations,” Panigirtzoglou wrote.

Bearing this in mind, we wanted to take a closer look at two stocks that just received a thumbs up from J.P. Morgan. With the firm’s analysts projecting more than 25% upside potential for each, we ran the tickers through TipRanks’ database to get the rest of the Street’s take. As it turns out, both have been praised by other analysts.

Viavi Solutions (VIAV)

Offering intuitive instruments, systems and technologies, Viavi Solutions helps service providers and IT organizations manage the network lifecycle for complex 5G and Fiber networks. Given the progress related to its field work and its compelling valuation, J.P. Morgan is jumping on board.

Representing the firm, analyst Samik Chatterjee tells clients the field instruments segment was hit hard by COVID-19. “VIAV on its latest earnings call highlighted that within the revenue shortfall in the NSE group, the portion attributable to lower demand in C1Q largely related to field instruments, which remains largely a book & ship business for every quarter... Production equipment has seen modest headwinds, more specific to end-markets with severe challenges, but have still been more resilient relative to Field instruments, which are impacted by the absence of technicians in the field,” he commented.

Having said that, Chatterjee argues that the easing of social distancing measures and outdoor field work restrictions will allow demand for test and measurement equipment to recover in the near-term. This is essential for VIAV as field instruments make up 60% of its core NE revenue. Long-term, the demand should remain largely unimpacted. He also pointed out, “Companies in our coverage universe are citing unchanged robust plans from service providers to drive 5G as well as 400G adoption, both of which VIAV has leverage to.”

On top of this, Chatterjee believes any M&A activity could serve as a major catalyst for shares. “The test & measurement landscape remains fragmented relative to suppliers and the disruption offers an opportunity for VIAV to further consolidate its position. Recent actions to establish a $300 million short-term credit line despite ample liquidity hints to similar intent,” the analyst explained.

Should the company acquire an asset with a complementary portfolio, Opex leverage could emerge as a possible synergy. Not to mention if the asset has profits from the U.S., Chatterjee thinks it “will enable the company to accelerate usage of NOLs driving a higher valuation.”

Expounding on VIAV’s valuation, the analyst stated, “Additionally, with VIAV shares now trading at ~18x NTM EPS, i.e., below recent year P/E of ~20x, unlike most companies in the coverage universe that are trading at premiums to their recent year valuation multiples on account of credit for trough earnings during the pandemic, we see an attractive opportunity for investors to position themselves for upside.”

Based on all of the above, Chatterjee upgraded his rating from Neutral to Overweight, and bumped up the price target from $14 to $16. This target implies shares could climb 25% higher in the next twelve months. (To watch Chatterjee’s track record, click here)   

Like Chatterjee, most other analysts also take a bullish approach. VIAV’s Strong Buy consensus rating breaks down into 7 Buys and 1 Hold. Given the $15.25 average price target, the upside potential lands at 20%. (See Viavi stock analysis on TipRanks)

Stratasys (SSYS)

As for J.P. Morgan’s second pick, we have Stratasys, which provides 3D printing and additive solutions. With its materials and services delivering speed, innovation, performance and customization, it’s no wonder the firm handed out a ratings upgrade.

Analyst Paul Coster highlights the fact that in Q2 and Q3, SSYS is going to place a significant focus on resizing actions in order to cut operating expenses by 10% and yield $30 million in annualized run-rate savings, which should also bode well for COGS.

Weighing in on this development, Coster said, “We previously anticipated cost reductions in 2020 but not of this magnitude, so we are only taking about $15 million out of 2021 PF operating expenses, nonetheless the action – overdue, in our view – is significantly accretive for shareholders. The new CEO is delivering for shareholders.”

While Coster reduced his estimates for 2020-2021 gross margins to account for lower product volumes, it should be noted that this is his second upgrade for SSYS recently. Citing the launch of new products expected to come over the next 12-18 months, the analyst believes the company will slowly start to see growth again. “With the expense reductions that the new CEO is pushing through, a return to modest growth should deliver operating leverage, and we think the stock will appreciate on upward revisions to estimates,” he stated.

That said, it will take some time for these gains to materialize, according to Coster. With COVID-19 still impacting activity in several of SSYS’s end-markets, including autos and aerospace, lackluster Q2 revenues and near-term pressure on gross margins could be on the horizon.

This fact, however, does not offset all of the positives, in Coster’s opinion. In line with his more bullish take, the analyst gave his rating a boost, from Neutral to Overweight. The price target got a lift as well, increasing to $22 from $19. Should the target be met, a twelve-month gain of 32% could be in store. (To watch Coster’s track record, click here)    

What does the rest of the Street think about SSYS? Opinions are split evenly down the middle, with the stock receiving 2 Buys and 2 Holds in the last three months. As a result, the consensus rating is a Moderate Buy. Additionally, the $20.33 average price target suggests 13% upside potential. (See Stratasys stock analysis on TipRanks)

To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.

The post J.P. Morgan Says These 2 Stocks Will Surge Over 25% From Current Levels appeared first on TipRanks Financial Blog.

Read More

Continue Reading


Revenge travel is coming to an end, says industry CEO — a recession will replace it

The CEO of Intercontinental Hotels Group says that the world has moved beyond revenge travel–even China.



Maybe revenge isn't so sweet anymore. Not so long ago the term "revenge travel" was making the rounds. The idea was that people were so fed up with the covid-19 pandemic lockdown that they packed their bags and took off for just about anywhere once travel restrictions started to ease.

Related: Delta adds a route U.S. tourists have been begging for

Last year, travel insurance company Allianz Partners projected that travel to Europe would soar 600% over 2021. “The pandemic made people realize you can't take travel for granted and many Americans are eager to visit Europe this summer,” Daniel Durazo, director of external communications at Allianz Partners USA, said in an April 2022 statement.

'Last stage of pent-up demand'

The Summer of '23 was also pretty strong, according to a survey by the Federal Reserve Bank of New York, which found that almost a third, or 32.8%, of all U.S. households took a vacation between May and August, up from 28.5% in August 2022 and a record high in data going back to 2015. However, it looks like the revenge travel upswing is coming to an end. The Federal Reserve's Beige Book said in September that consumer spending on tourism was stronger than expected, "surging during what most contacts considered the last stage of pent-up demand for leisure travel from the pandemic era." Elie Maalouf also thinks that the revenge travel dish has gone cold. The CEO of Intercontinental Hotels Group  (IHG) - Get Free Report said in an interview with CNBC that he believes pent-up demand is over. "People started traveling really by the end of 2020 as restrictions started to lift,” he said. “So we’re really past revenge travel — even in China.” Intercontinental Hotel Group operates hotels under several brand names, including Regent, Crowne Plaza, Holiday Inn Club Vacations, and Candlewood Suites. The company’s latest quarterly update showed travel demand remained strong during the close of the summer travel season. “We think we’re in a sustainable place,” Maalouf said. “Our bookings for groups and meetings going into 2024 and beyond are the strongest we’ve seen in a very long time.”

Average room rates increase

IHG’s third quarter trading update showed the company’s revenue per available room — or “revpar” — was up 10.5% compared to third quarter 2022, and nearly 13% higher compared with the third quarter of 2019, which was before the pandemic. This is despite a 3% drop in revpar, compared to 2019, in large cities in Greater China, which are more dependent on international travelers. Maalouf said that lack of “airlift,” or flight capacity, into China is below 50% of prepandemic levels, which is affecting travel recovery in cities like Beijing, Shanghai, Guangzhou and Shenzhen. “But if you look at the country as a whole, travel — which is mostly domestic in China — it’s recovered well above 2019,” he said, adding that more than 80% of IHG’s business in China is in mid-sized to smaller cities. Occupancy levels in the third quarter at IHG hotels was 72% — just 1% shy of pre-pandemic levels, according to the quarterly update. But average room rates have jumped well above 2019 levels — up nearly 6% in Greater China, 15% in the Americas, and 24% in Europe, Middle East, and Africa (EMEA) and Asia. But rising rates are barely keeping up with inflation, said Maalouf. “Room rates have not really exceeded inflation in any of our markets,” he said. “I think people’s willingness to travel is exhibited by the fact they’re willing to pay.” Get investment guidance from trusted portfolio managers without the management fees. Sign up for Action Alerts PLUS now.

Read More

Continue Reading

Spread & Containment

How Novo Nordisk’s Rybelsus went from pandemic washout to blockbuster amid the GLP-1 boom

Novo Nordisk’s Rybelsus pill was long expected to be a hit out of the gate.
The Danish drugmaker cashed in a priority review voucher in early 2019 for…



Novo Nordisk’s Rybelsus pill was long expected to be a hit out of the gate.

The Danish drugmaker cashed in a priority review voucher in early 2019 for what would be the first oral GLP-1, primed by positive studies showing reduced blood sugar in patients with type 2 diabetes. Analysts and company insiders anticipated blockbuster status for the oral version of semaglutide, with peak sales expected to hit up to $5 billion — and potentially follow the trajectory of its sibling injectable Ozempic, which reached $1.6 billion in sales in less than two years.

Camilla Sylvest

“We have another monumental event with the world’s first oral GLP-1,” commercial strategy chief Camilla Sylvest said in November 2019. “This is not just a compressed pill. This is a pill that has a clinical profile to compete and [that has] the oral administration to compete. It’s an unbelievable opportunity for us.”

But then health officials declared the Covid-19 pandemic in March 2020, and everything changed. Novo’s sales reps couldn’t do in-person meetings. No commercial advertising shoots were allowed. Patients scrapped going to the doctor for elective purposes. As Novo’s launch plans crumbled, so did the promise of Rybelsus.

Three and a half years later, amid a frenzy of all things GLP-1, Rybelsus has come back to life — albeit slowly, and with skepticism over its efficacy for weight loss compared to injectables.

There’s fresh enthusiasm for other oral GLP-1s in development, and Ozempic, approved for type 2 diabetes, is now a household name. That’s in part because people have been taking Ozempic — and more recently, Rybelsus — off-label for weight loss amid shortages of Wegovy, the injectable version of semaglutide approved for obesity. But there are also concerns about tolerability in a market that’s increasingly crowded.

The pandemic disruptor

Back in late 2019 and early 2020, everything was going as planned for Rybelsus. The FDA approved the pill in 3 mg, 7 mg and 14 mg doses. Novo had expanded its manufacturing facilities in North Carolina, and it was working on plans for a broad direct-to-consumer ad campaign, including mainstream TV commercials.

The company was so confident that it priced Rybelsus on par with Ozempic at about $770 per month, to the surprise of some analysts at the time. The commercial strategy was to market its GLP-1 drugs side-by-side, positioning Ozempic as the first and preferred injectable for type 2 diabetes and Rybelsus as the first and preferred oral medication, Sylvest and then-chief scientific officer Mads Krogsgaard Thomsen said in an investor call, according to AlphaSense transcripts.

Mads Krogsgaard Thomsen

“With our two recent GLP-1 products, Ozempic and Rybelsus, we want to redefine type 2 diabetes treatment,” Novo wrote in its 2019 annual report. “We are at the forefront of innovation in the GLP-1 class and orally administered delivery devices and are pursuing several therapeutic opportunities with semaglutide.”

But then came Covid, and Novo had to switch gears from the splashy DTC ad campaign to animated work with an upbeat soundtrack that eventually debuted in the autumn of 2020. For the first six months of that year, Rybelsus brought in just $92 million.

By 2022, however, it rang up sales of $1.7 billion, more than twice its 2021 total, likely fueled by the demand for semaglutide sibling brand Wegovy, which was approved to treat obesity in mid-2021. Novo is reporting Q3 sales next week, with Rybelsus likely on track to top $2 billion in sales this year. Novo declined comment for this story, citing its quiet period ahead of its Q3 earnings release.

Off-label for weight loss

As Wegovy took off and supplies waned, clinicians used their off-label prescribing power to redirect desperate obesity and overweight patients to Ozempic.

Some physicians turned to Rybelsus. Tracking off-label prescribing is difficult, but data show that there were 157,500 Medicaid prescriptions for Rybelsus for weight loss in 2022. In the same year, Wegovy had 30,100 Medicaid prescriptions for weight loss, while Eli Lilly’s type 2 diabetes treatment Mounjaro had 30,700, according to a KFF analysis in August. Ozempic was the lead seller among Medicaid populations, at more than 978,000 prescriptions.

That said, Rybelsus does not seem to be as effective at weight loss as the other approved GLP-1s.

Diana Thiara

Diana Thiara, medical director of the University of California, San Francisco’s weight management program, calls the new GLP-1 meds in general “amazing,” citing an example of a patient taken off a lung transplant list after losing weight and improving lung function. But she also acknowledges the social trends driving low-dose oral uptake by “people so desperate to lose weight.”

“I have one patient who can’t even use our MyChart electronic health communications, but tells me about what Reddit says,” she said. “Reddit and TikTok people say stuff, but that’s not really what the evidence shows right now.”

Rybelsus’ current highest dose is equivalent to Ozempic’s lowest dose, though some experts say the lower doses can still help patients lose weight.

“The lower doses, based on my experience, are effective for weight loss,” said Kristin Baier, clinical director at Calibrate, a telehealth weight loss startup founded in 2020. “When used along with lifestyle changes, we have seen patients achieve up to 20% weight loss on the lower doses of oral semaglutide.”

The future of oral GLP-1 weight loss drugs

Novo is currently testing higher doses at 25 mg and 50 mg doses of Rybelsus in the Pioneer Plus (with type 2 patients) and Oasis (with people with overweight or obesity) trials against the 14 mg currently approved by the FDA. The results, published this spring and summer, show up to 15% bodyweight loss, which is on par with Ozempic and Wegovy.

Clinicians are also encouraged by differentiated competing oral candidates, like Pfizer’s danuglipron and Lilly’s orforglipron, both in Phase II trials. The candidates are non-peptide GLP-1s and can be taken with food. Rybelsus is directed to be taken on an empty stomach with small sips of water and a wait time of 30 minutes before other medications or food.

“With Novo Nordisk expected to file for the higher dose approval, I believe there’s going to be an uptake that hopefully would help with some of the manufacturing supply issues we see [with injectable semaglutides],” said Weight Watchers medical director Spencer Nadolsky. “It will be nice to have the larger dose option when it’s available.”

Yet, it’s not all upside on the weight loss front for Rybelsus.

“It’s equivalent to a pretty low dose of Ozempic. So in terms of weight loss, we don’t see much weight loss in terms of the average person at that dose of Rybelsus,” Thiara said.

She also has some concerns about the higher doses and gastrointestinal issues and tolerability.

“People just seem to have more side effects with oral Rybelsus than they do with the equivalent Ozempic dose,” Thiara said, adding that she does think it will be approved. “But head-to-head right now, with no supply chain issues and if 50 milligrams was on the market and I had a patient who was open to anything injectable or oral, I would probably skew towards injectable.”

Read More

Continue Reading

Spread & Containment

Popular mall retailer Express facing potential Chapter 11 bankruptcy

The brand has seen its sales fall and its costs rise dramatically which has caused it to fall behind on some bills.



The Covid pandemic hit malls hard. Even when they were allowed to operate, many people did not want to be confined in a tight space with other people breathing near them.

Mask rules and social distancing requirements made the once-fun experience of just wandering around a mall a whole lot less fun. Even when vaccines were introduced and life returned mostly to normal, some malls — generally the weaker ones before Covid — continued to struggle. 

Related: Beloved discount retailer faces significant bankruptcy risk

So far, no major mall-based retailer has filed for a post-Covid bankruptcy. Bed Bath & Beyond, Christmas Tree Shops, and Tuesday Morning, all of which went bankrupt and were liquidated, generally were located in strip malls. The same is true for Party City and David's Bridal, two chains that managed to survive their Chapter 11 filings.

But, mall retailers are not immune from the problems caused by Covid, where sales dropped to near zero for months, but expenses did not go away. That led to increased debt.

The pandemic also changed consumption habits. Some people still work from home full time and many Americans are now in hybrid work situations. That has changed their wardrobe needs and that's bad news for certain retailers, including Express, a mall favorite with over 500 stores nationwide.     

"Express is truly on a respirator and teetering on possible bankruptcy,” Shawn Grain Carter, a retail consultant and Fashion Institute of Technology professor, told RetailDive.

Some malls have seen smaller crowds, but that is not universal.

Image source: Getty Images

Express is struggling in many ways

Express has seen its sales fall and its cost rise,

The retailer’s consolidated net sales dropped 6.4% to $435.3 million, according to its second-quarter earnings report. In addition, the company’s selling, general, and administrative expenses have increased to $146.1 million (33.6% of net sales) compared to the second quarter in 2022. 

Perhaps most damningly, the chain's debt has consistently grown. In fact, its total debt was $220.8 million at the end of Q2 2023, compared to $202.2 million at the end of Q2 2022 and $122 million at the end of Q4 2022. 

"Over the last few months, speculation has been mounting about apparel retailer Express’ financial state. While some might speculate that one big thing has caused the retailer’s failure, that’s just not how bankruptcies work. Several things have been going wrong over a prolonged period," Matthew Debbage, Creditsafe CEO of the Americas and Asia, told TheStreet via email.  

According to Creditsafe data, 35% of the company’s owed payments are past due, which amounts to over $3 million.

"On top of this, Creditsafe data reveals that the value of these late payments is well over $3 million. While this might not seem like a big chunk of money compared to Express’ annual revenue, the fact that the retailer’s DBT (Days Beyond Terms) has increased consistently for the last six months indicates that its cash reserves are likely low, which will only drop even lower if sales continue to decline, operating costs keep rising and its debt load grows," he said.

It's a slowly rising tide that could ultimately swallow the company.

"When you combine all these factors, I can see why some analysts are speculating that the company could be at high risk of bankruptcy," he wrote.

Debbage believes the company should be taking steps to prepare for a Chapter 11 filing (even if it ends up not needing one).

"What Express needs to be thinking about right now is how it can cut operating expenses with a recession looming and consumer spending expected to drop significantly," he wrote. "The retailer’s finance leadership should also be prioritizing data, analytics and technology to make sure it has the right financial data so it can get a clear picture of its financial affairs, especially if it tries to secure financing to stave off bankruptcy."

Express did not return an immediate request for comment sent to its investor relations email.

Read More

Continue Reading